drugset / Trial / NCT05900401
Delayed Tolerance Through Mixed Chimerism
Phase 1/2
Recruiting
20 enrolled
Massachusetts General Hospital
ITB-Med LLC · collabOssium Health, Inc. · collab
Non-randomizedParallel-groupSingle-blindTreatment
Summary
This study will examine the safety and effectiveness of a bone marrow transplant after kidney transplant (from either a living or deceased donor). An investigational medication and other treatments will be given prior to and after the transplant to help protect the transplanted kidney from being attacked by the body's immune system
Timeline
- Start
- 2023-10-01
- Primary completion
- 2031-12
- Completion
- 2032-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Cyclophosphamide | Other / unclassified | 30 mg/kg | — |
| Background | Fludarabine | Small molecule | 15 mg/m2 | — |
| Background | MEDI-507 | Monoclonal antibody | — | — |
| Background | Rituximab | Monoclonal antibody | — | — |